BTOG 2022 Summer Meeting | Improving immunotherapy outcomes in mesothelioma

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, discusses improving on the outcomes of immunotherapy in mesothelioma. A predominant unmet need in mesothelioma is answering the question of whether immunotherapy should be combined with chemotherapy. Dr Shah highlights the Phase III BEAT-meso (NCT03762018) trial which investigated atezolizumab plus bevacizumab in combination plus standard chemotherapy and the control arm of chemotherapy doublet plus bevacizumab. This interview took place at the BTOG 2022 Summer Meeting congress in London.